

Registered & Corporate Office:

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5, Opp. SBI Executive Enclave, Banjara Hills, Hyderabad - 500 034, Telangana, INDIA.

Tel: +91-40-2525 9999,3535 9999

Fax: +91-40-2525 9889

CIN: L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 08th November, 2024

To

The Manager,

Corporate Filings Department,

BSE Limited,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001.

The Manager,

Listing Compliance Department, National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Subject: Outcome of Board Meeting and Financial Results:

With reference to the cited subject matter, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e., 08th November, 2024, have *inter-alia*, transacted the following item(s) of the Agenda:

- Approved the standalone and consolidated un-audited Financial Results for the second quarter and half year ended 30th September, 2024 and a copy of the same is enclosed along with Limited Review Report of the Statutory Auditors of the Company.
- Approved reconstitution of the Nomination and Remuneration Committee of the Board w.e.f. 08th November, 2024 with the following members

Mrs. Shanti Sree Bolleni

Chairman

Dr. Suresh Kumar Gangavarapu

Member

Dr. Sunkara Venkata Satya Shiva Prasad

Member

The meeting of Board of Directors commenced at 04.00 p.m. and concluded at about 6.35 p.m.

Please take the above intimation on your records.

Hyderabac

Thanking you

Yours faithfully

For SMS Pharmaceuticals Limited

Thirumalesh Tumma

Company Secretary & Compliance Officer

SURYANARAYANA & SURESH

Chartered Accountants



Flat # C1, Millenium House, # 8-2-601/B, Road No. 10, Near Zaheer Nagar Cross Road, Banjara Hills, Hyderabad - 500 034.

©: 040-23386783 / 35835109

yderabad

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors
SMS Pharmaceuticals Limited
Hyderabad.

- 1. We have reviewed the accompanying statement of unaudited financial results of SMS Pharmaceuticals Limited ("the Company"), for the quarterand half year ended 30th September 2024 ('the statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 2. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited, primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures to financial data and thus provide less assurance than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results has not been prepared in all material aspects in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Hyderabad F.R.NO.006631S

Place: Hyderabad Date: 08.11.2024

UDIN: 24227679BKDISZ6011

For Suryanarayana & Suresh., Chartered Accountants Reg. No.006631S

V Nagendra Rao Partner

M.No. 227679

SMS PHARMACEUTICALS LIMITED

(CIN: L24239TG1987PLC008066)

Regd. Office: Plot No.72, H.No.8-2-334/3&4, Road No.5, Opp.SBI Executive Enclave, Banjara Hills, Hyderabad-500 034, Telangana, India Tel: +91-40-35359999 / 2525 9999, Fax :+91-40-2525 9889 ; Email : info@smspharma.com

Statement of Standalone Un-Audited Financial Results for the Quarter and Half Year Ended 30th September, 2024

(Rs. In Lakhs)

							(NS. III LAKIIS)
	Particulars		Quarter Ended		Half Yea	Year ended	
S.No		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	19,674.79	16,445.13	16,664.35	36,119.93	30,198.29	70,926.34
2	Other Income	130.46	136.76	81.03	267.22	132.32	445.97
3	Total Revenue	19,805.25	16,581.89	16,745.38	36,387.15	30,330.61	71,372.31
4	Expenses (a) Cost of Materials Consumed (b) Changes in Inventories (c) Manufacturing Expenses (d) Employee Benefits Expense (e) Finance Cost (f) Depreciation and Amortization Expense	15,837.66 (4,307.67) 2,199.08 1,792.55 460.58 862.03	1,819.47 1,688.38 466.71 838.15	10,359.32 (578.08) 1,869.01 1,457.33 557.22 789.96	26,566.45 (6,235.45) 4,018.55 3,480.94 927.29 1,700.18	3,207.00 2,905.61 1,189.49 1,559.09	42,504.00 (100.00) 7,344.30 6,414.97 2,345.68 3,151.57
	(g) Other Expenses	967.00	789.78	774.61	1,756.77	1,454.05	3,078.62
	Total Expenses - (a to g)	17,811.23	14,403.50	15,229.37	32,214.73	27,498.94	64,739.14
5	Profit Before Exceptional Items and Tax (3-4)	1,994.02	2,178.39	1,516.01	4,172.42	2,831.67	6,633.17
6 7 8	Exceptional items Profit Before Tax (5-6) Tax Expenses	1,994.02	2,178.39	1,516.01	4,172.42	2,831.67	6,633.17
0	(a) Current Tax relating to Current Period/Year (b) Current Tax relating to Earlier Period/Year	470.00	530.00	310.00	1,000.00	650.00	1,500.00 12.79
	(c) Deferred Tax	98.20 568.20	15.56 545.56	1.27 311.27	113.76 1,113.76	48.65 698.65	177.89 1,690.68
9	Net Profit / (Loss) for the Period/Year (7-8)	1,425.82	1,632.83	1,204.74	3,058.66	2,133.02	4,942.49
10	Other Comprehensive Income (OCI): Items that will not be reclassified to profit or Loss: Income Tax effect on the above	5.99 (1.51) 4.48	(1.94) 0.49 (1.45)	(8.23) 2.07 (6.16)	4.05 (1.02) 3.03	(15.77) 3.97 (11.80)	7.04 (1.77) 5.27
11	Total Comprehensive Income for the Period/Year (9+10)	1,430.30	1,631.38	1,198.57	3,061.69	2,121.22	4,947.76
12	Earning Per Equity Share of Re.1/- each Basic / Diluted (not annualised)	1.68	1.93	1.42	3.61	2.52	5.84
	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						56,202.26



Standalone Un-Audited Statement of Assets and Liabilities as at 30th September, 2024

(Rs.in Lakhs)

Sr. No. Particulars 30.09.202 (Unaudited 1) Non-Current Assets	As at
No. Particulars 30.09.202 (Unaudited	Asat
A ASSETS (Unaudited	4 31.03.2024
	d) (Audited)
1 Non-Current Assets	
i i i ou - ou i ent Assets	
(a) Property, Plant and Equipment 42,380.2	43,418.90
(b) Capital Work-in-Progress 9,449.6	200
(c) Right-of-use Assets	
(d) Intangible Assets 246.3	
(e) Financial Assets:	200.00
(i) Investments 4,509.6	4 ,509.67
(ii) Bank Balances 296.	
(iii) Other Financial Assets 564.9	
Sub Total :Non-Current Assets 58,694.9 2 Current Assets	53,435.67
(a) Inventories 31,527.	16 23,369.78
(b) Financial Assets	
(i) Trade Receivables 21,337.8	
(ii) Cash and Cash Equivalents 890.0	3,603.95
(iii) Bank Balances	
(Other than (ii) above)	16.30
(iv) Other Financial Assets 1,182.5	327.86
(c) Other Current Assets 3,112.8	2,275.45
(d) Current Tax Asset (Net)	172.82
Sub Total : Current Assets 58,194.2	22 53,389.48
TOTAL ASSETS 1,16,888.7	
B EQUITY AND LIABILITIES	73 1,06,825.15
1 Equity:	040.50
(a) Equity Share Capital 846.5	
(b) Other Equity 58,924.3 Sub-Total -Shareholders' funds 59,770.8	
and artifaction and artifaction of the state	57,048.78
Liabilities:	l l
2 Non-Current Liabilities	
2 Non-Current Liabilities (a) Financial Liabilities	
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings 15,061.3	12,208.63
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities 15,061.3	, -
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions 15,061.3	- 00 116.01
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) 15,061.3 15,061.3 123.0 4,393.6	
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities 19,577.9	
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities 19,577.9	
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (a) Financial Liabilities	
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities 19,577.9	116.01 64 4,279.89 66 16,604.53
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (a) Financial Liabilities	116.01 34 4,279.89 16,604.53 15,809.24
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (i) Borrowings 15,061.3 4,393.6 Sub-Total -Non-Current Liabilities 19,577.9 13,455.6	116.01 34 4,279.89 16,604.53 15,809.24
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities 13,455.6 (iii) Lease Liabilities	116.01 4,279.89 16,604.53 15,809.24 59.18
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (ii) Trade Payables: (a) Dues to Micro & Small Enterprises (b) Dues to Creditors Otherthan Micro & Small Enterprises 21,453.1	116.01 34 4,279.89 36 16,604.53 39 15,809.24 31 59.18 95.79
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (ii) Trade Payables: (a) Dues to Micro & Small Enterprises (b) Dues to Creditors Otherthan Micro & Small Enterprises 21,453.1	116.01 34 4,279.89 36 16,604.53 31 59.18 35 95.79 36 15,036.48
Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (ii) Lease Liabilities (ii) Trade Payables: (a) Dues to Micro & Small Enterprises (b) Dues to Creditors Otherthan Micro & Small Enterprises (iii) Other Financial Liabilities 1,877.3	116.01 4,279.89 66 16,604.53 15,809.24 59.18 05 95.79 11 15,036.48 1,585.16
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (ii) Trade Payables: (a) Dues to Micro & Small Enterprises (b) Dues to Creditors Otherthan Micro & Small Enterprises (iii) Other Financial Liabilities	116.01 4,279.89 66 16,604.53 15,809.24 59.18 05 95.79 11 15,036.48 1,585.16 60 103.04
2 Non-Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) Sub-Total -Non-Current Liabilities (a) Financial Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (ii) Trade Payables: (a) Dues to Micro & Small Enterprises (b) Dues to Creditors Otherthan Micro & Small Enterprises (iii) Other Financial Liabilities	116.01 34 4,279.89 36 16,604.53 31 59.18 35 95.79 36 15,036.48 37 15,036.48 38 1,585.16 39 103.04 482.95

SMS Pharmaceuticals Limited Standalone Unaudited Statement of Cash Flow for the Half Year Ended September 30,2024

S No	Particulars	For the Half Year	(Rs.in Lakhs) For the Year ended 31.03.2024
Α	Cash Flow from Operating Activities	ended 30.09.2024	31.03.2024
,,,	Profit Before Tax	4,172.41	6,633.17
	Adjustments for:	7,172.71	0,033.17
	Depreciation and Amortisation Expense	1,700.18	3,151.57
	Interest Income	(9.52)	(16.77)
	Interest meonic	10.80	12.00
	Interest on Borrowings	847.20	2,235.79
	Provision for Employee Benefits	13.58	(20.33)
	Amortisation of Transaction Cost on Borrowings	7.34	15.55
	Profit on Sale of Assets		
	Loss on Sale of Assets	(2.25)	(4.27)
	LOSS OIT Sale Of Assets	6,739.74	0.54 12,007.25
		0,733.74	12,007.25
	Change in Operating Assets and Liabilities		
	(Increase)/Decrease in Trade Receivables	2,285.45	(8,784.70)
	(Increase)/Decrease in Inventories	(8,157.38)	(1,019.84)
	(Increase)/Decrease in Other Non Current Financial Assets	(47.85)	(8.55)
	(Increase)/Decrease in Other Non Current Asset	150.32	(826.08)
	(Increase)/Decrease in Other Current Financial Assets	(845.44)	331.15
	(Increase)/Decrease in Other Current Assets	(838.27)	(381.61)
	(Increase)/Decrease in Prepaid Taxes	35.59	430.64
	Increase/(Decrease) in Trade Payables	6,380.89	4,386.77
	Increase/(Decrease) in Other Current Financial Liabilities	67.05	224.61
	Increase/(Decrease) in Other Current Liabilities	86.84	192.83
	more ase, (a concase) in other same in classifica	(882.80)	(5,454.78)
	Cash generated from Operations	5,856.94	6,552.47
	Income Taxes Paid	(990.00)	(1,540.00)
_	Net Cash Inflow from Operating Activities "A"	4,866.94	5,012.47
В	Cash flow from Investing Activities		
	Purchase of Property, Plant and Equipment	(7,117.18)	(5,216.00)
	Sale of Property, Plant and Equipment	3.20	8.80
	Investment in Deposits	(0.24)	(0.65)
	Investment in Margin Money Deposits	(27.34)	(15.22)
	Interest Received on Deposits	0.30	15.87
	Net Cash Inflow (Outflow) from Investing Activities "B"	(7,141.26)	(5,207.20)
С	Cash Flow from Financing Activities		
-	Proceeds from Long Term Borrowings	5,034.00	4,508.63
	Repayment of Long Term Borrowings	(2,267.35)	(3,776.36)
	Net Proceeds from Short Term Borrowings	(2,278.55)	2,020.71
	Interest paid on Borrowings	(874.05)	(2,175.16)
	Repayment of Lease Liability Proceeds from Share Warrants(Net of issue expenses)	(52.67)	(103.74)
	The state of the s	(0.97)	2,847.78
	Dividend Paid to company's shareholders	(420 50)	(253.96)
	Net Cash Inflow (Outflow) from Financing Activities "C"	(439.59)	3,067.90
	Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C) Cash and Cash Equivalents at the beginning of the	(2,713.89)	2,873.17
	Financial Year	3,603.95	730.78
		3,003.33	730.70
	Cash and Cash Equivalents at end of the Year	890.06	3,603.95



Notes:

- The above standalone un-audited financial results for the quarter ended September 30, 2024 have been reviewed by the Audit Committee on November 07, 2024 and approved by the Board of Directors at their meeting held on November 08, 2024. The statutory auditors of the Company have carried out a limited review on standalone financial results for the quarter ended September 30, 2024 and expressed an unmodified conclusion thereon.
- These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- As approved by the Members of the company at the 36th Annual General Meeting held on September 30,2024, the company has disbursed on October 04, 2024 a dividend of Re.0.40 per equity share of Re.1/- each for the year ended March 31, 2024, aggregating to Rs.308.36 lakhs (Including an amount of Rs 30.25 lakhs towards Tax Deducted at Source).

5 Figures for the previous period have been reclassified/ regrouped wherever necessary to confirm to current period's classification.

For SMS Pharmaceuticals Limited

Place: Hyderabad

Date: 08 November, 2024

Ramesh Babu Potluri
Chairman and Managing Director

Hyderabad

DIN: 00166381

SURYANARAYANA & SURESH

Chartered Accountants



Flat # C1, Millenium House, # 8-2-601/B, Road No. 10, Near Zaheer Nagar Cross Road, Banjara Hills, Hyderabad - 500 034.

©: 040-23386783 / 35835109

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors
SMS Pharmaceuticals Limited
Hyderabad.

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited financial results of M/s SMS Pharmaceuticals Limited("the holding Company") and its share of the net profit after tax and other comprehensive income of its associate (the holding company and its associate hereinafter referred to as "the Group"), for the quarter and half year ended September 30, 2024 ("the Statement"). The Statement is being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015").
- 2. This Statement, which is the responsibility of the holding company's management and has been approved by the holding company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review is limited, primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures to financial data and thus provide less assurance than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



- 4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
- 5. The Statement includes the results of the following associate entity/joint venture:
 - a) M/s VKT Pharma Private Limited
 - b) M/s Chemo SMS Enterprises SL
- 6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 7, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 7. The consolidated unaudited financial results includes the holding company's share of profit after tax of Rs.23.75 Lakhs and Rs.34.23 Lakhs for the quarter and half year ended September 30, 2024 respectively and other comprehensive income of Rs.0.39 Lakhs and Rs.0.78 Lakhs for the quarter and half year ended September 30,2024,as considered in the statement, in respect of the associate namely M/s VKT Pharma Private Limited which have been reviewed by their auditor.
- 8. The consolidated financial results also includes the unaudited financial results of joint venture namely M/s Chemo SMS Enterprises SL in which there is no operations during the quarter ended September 30, 2024. Hence, there is no significant effect on the financial statements and not material to the group.

9. Our conclusion on the Statement is not modified in respect of the above matters.

Hyderabad

Place: Hyderabad

Date: 08.11.2024

For Suryanarayana & Suresh.,

Casualo

Chartered Accountants

Reg. No.006631S

UDIN:

24227679BKDITA8279

V Nagendra Rao

Partner

M. No. 227679

SMS PHARMACEUTICALS LIMITED

(CIN: L24239TG1987PLC008066)

Regd. Office: Plot No.72, H.No.8-2-334/3&4, Road No.5, Opp.SBI Executive Enclave, Banjara Hills, Hyderabad-500 034, Telangana, India Tel: +91-40-35359999 / 2525 9999, Fax:+91-40-2525 9889; Email: info@smspharma.com

Statement of Consolidated Un-Audited Financial Results for the Quarter and Half Year Ended 30th September, 2024

(Rs. In Lakhs)

S.No Particulars 30,09,2024 30,09,2023 30,09,203 30,09							(Rs. In Lakhs)	
Revenue From Operations						Year ended		
1 Revenue From Operations 19,674.79 16,446.13 16,684.35 36,119.93 30,198.29 70,926.34 2 Other Income 130.46 136.76 81.03 267.22 132.32 445.91 3 Total Income 19,805.25 15,581.89 15,745.38 36,387.16 30,330.61 71,372.31 4 Expense (a) Cost of Malerialis Consumed (b) Changes in Inventories (4,307.67) (1,724.16 10,359.39 28,601.49 19,531.53 42,526.48 (b) Changes in Inventories (4,307.67) (1,777.90) (578.09) (2,303.37) (100.00 (1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 (c) Manufacturing Expenses (2,199.08 1,819.47 1,889.01 4,418.55 3,207.00 73,443.34 (d) Employee Benefits Expense 1,792.55 1,489.01 4,418.55 3,207.00 73,443.34 (e) Finance Cost (40.58) 466.71 557.22 927.29 1,189.49 2,245.86 (f) Depreciation and Amerization Expense 862.03 838.15 789.96 1,700.18 1,559.09 3,151.57 (g) Other Expenses - (a to g) 17,850.39 14,398.87 15,229.44 32,245.77 27,546.40 64,761.65 (g) Other Expenses - (a to g) 17,850.39 14,398.87 15,229.44 32,245.77 27,546.40 64,761.65 (g) Exceptional Items and Tax (3-4) 1,954.36 2,183.02 1,515.94 4,137.38 2,784.21 6,610.61 Exceptional Items (5) 1,954.36 2,183.02 1,515.94 4,137.38 2,784.21 6,610.61 Exceptional Items (5) 1,954.36 2,183.02 1,515.94 4,137.38 2,784.21 6,610.61 Exceptional Items (6) 1,954.36 1,277 1,113.76 48.65 177.86 1,277 1,278.67 1,27	S.No	Particulars						
2 Other Income 130.46 136.76 81.03 287.22 132.32 445.97 Total Income 19,805.25 16,881.89 16,745.38 36,387.16 30,330.61 71,372.37 Expenses (a) Cost of Materials Consumed (b) Changes in Inventories (c) Manufacturing Expenses (d) Expenses (e) Finance Cost (d) Employee Benefits Expense (e) Finance Cost (e) Finance Cost (f) Depreciation and Amortization Expense (g) Cher Expenses (h) Depreciation and Amortization Expense (g) Cher Expenses (g)			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Expenses (a) Corrent Tax relating to Current Period/Year (b) Current Tax relating to Earlier Period/Year (c) Deferred Tax (c) Deferred T	1	Revenue From Operations	19,674.79	16,445.13	16,664.35	36,119.93	30,198.29	70,926.34
Expenses	2	Other Income	130.46	136.76	81.03	267.22	132.32	445.97
(a) Cost of Materials Consumed (b) Changes in Inventorias (c) Manufacturing Expenses (d) Employee Benefits Expense (d) Employee Benefits Expense (d) Employee Benefits Expense (e) Finance Cost (f) Depreciation and Amortization Expense (g) Other Expenses (g) Oth	3	Total Income	19,805.25	16,581.89	16,745.38	36,387.15	30,330.61	71,372.31
Exceptional items Profit Before Tax (5-6) Tax Expenses (a) Current Tax relating to Current Period/Year (b) Current Tax relating to Earlier Period/Year (c) Deferred Tax Net Profit / (Loss) for the Period/Year (7-8) Net Profit / (Loss) after taxes and share of profit/(loss) from associate (9+10) Current Tax will not be reclassified to profit or Loss: (iii) Comer Tax effect on the above in Associate (iv) Share of Income Tax effect on the above in Associate (viv) Share of Income Tax effect on the above in Ass	4	(a) Cost of Materials Consumed (b) Changes in Inventories (c) Manufacturing Expenses (d) Employee Benefits Expense (e) Finance Cost (f) Depreciation and Amortization Expense (g) Other Expenses	(4,307.67) 2,199.08 1,792.55 460.58 862.03 967.00	(1,927.78) 1,819.47 1,688.38 466.71 838.15 789.78	(578.08) 1,869.01 1,457.33 557.22 789.96 774.61	(6,235.45) 4,018.55 3,480.94 927.29 1,700.18 1,756.77	(2,300.37) 3,207.00 2,905.61 1,189.49 1,559.09 1,454.05	42,526.49 (100.00) 7,344.30 6,414.97 2,345.68 3,151.57 3,078.62 64,761.63
Exceptional items Profit Before Tax (5-6) Tax Expenses (a) Current Tax relating to Current Period/Year (b) Current Tax relating to Earlier Period/Year (c) Deferred Tax Net Profit / (Loss) for the Period/Year (7-8) Net Profit / (Loss) after taxes and share of profit/(loss) from associate (9+10) Current Tax will not be reclassified to profit or Loss: (iii) Comer Tax effect on the above in Associate (iv) Share of Income Tax effect on the above in Associate (viv) Share of Income Tax effect on the above in Ass	5	Profit Refere Exceptional Items and Tay (3.4)	1 954 36	2 183 02	1 515 94	1 137 38	2 784 21	6 610 68
Profit Before Tax (5-6) 1,954.36 2,183.02 1,515.94 4,137.38 2,784.21 6,610.66 Tax Expenses (a) Current Tax relating to Current Period/Year 470.00 530.00 310.00 1,000.00 650.00 1,500.00 (b) Current Tax relating to Earlier Period/Year 470.00 530.00 310.00 1,000.00 650.00 1,500.00 (c) Deferred Tax 98.20 15.56 1.27 113.76 48.65 177.85 568.20 545.56 311.27 1,113.76 698.65 1,690.66 Net Profit / (Loss) for the Period/Year (7-8) 1,386.16 1,637.46 1,204.68 3,023.62 2,085.56 4,920.00 Share of Profit/(loss) in associate company,net of tax 23.75 10.48 (32.17) 34.23 21.11 62.60 Net Profit / (Loss) also associate company,net of tax 23.75 10.48 (32.17) 34.23 21.11 62.60 Net Profit / (Loss) also associate company,net of tax 23.75 10.48 (32.17) 34.23 21.11 62.60 Other Comprehensive Income (OCI): (ii) Income Tax effect on the above (1,59) (1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 (iii) Income Tax effect on the above in Associate 0.53 0.52 1.39 1.05 2.75 1.99 (iii) Share of Income Tax effect on the above in Associate 0.53 0.52 1.39 1.05 2.75 1.99 (iv) Share of Income Tax effect on the above in Associate 0.14 (0.14) (0.14) (0.35) (0.27) (0.71) (0.55) Total Comprehensive Income for the Period/Year (11+12) 1,414.78 1,646.87 1,167.38 3,061.66 2,096.91 4,989.34 Total Comprehensive Income for the Period/Year (11+12) 1,414.78 1,646.87 1,167.38 3,061.66 2,096.91 4,989.34 Total Comprehensive Income for the Period/Year (11+12) 1,414.78 1,646.87 1,167.38 3,061.66 2,096.91 4,989.34 Total Comprehensive Income for the Period/Year (11+12) 1,414.78 1,646.87 1,167.38 3,061.66 2,096.91 4,989.34 Total Comprehensive Income for the Period/Year (11+12) 1,414.78 1,646.87 1,167.38 3,061.66 2,096.91 4,989.34 Total Comprehensive Income for the Period/Yea			1,554.50	2,103.02	1,513.54	4,137.30	2,704.21	0,010.00
Tax Expenses (a) Current Tax relating to Current Period/Year 470.00 530.00 310.00 1,000.00 650.00 1,500.00 (b) Current Tax relating to Earlier Period/Year			1.054.26	2 492 02	1 515 04	4 127 20	2 704 24	6 610 69
(a) Current Tax relating to Current Period/Year (b) Current Tax relating to Earlier Period/Year (c) Deferred Tax 98.20		The second of th	1,954.36	2,183.02	1,515.94	4,137.38	2,784.21	6,610.68
(c) Deferred Tax (d) Deferred Tax (e) Deferred Tax (f) Deferred Tax (g) 88.20 (g) 15.56 (g) 1.27 (g) 113.76 (g) 48.65 (g) 177.86 (g) 568.20 (g) 545.56 (g) 311.27 (g) 1,113.76 (g) 698.65 (g) 1,690.66 (g) 1,386.16 (g) 1,409.91 (g) 1,647.94 (g) 1,72.51 (g) 1,647.94 (g		500 2730 & 15.000 A COLO A COL	470.00	530.00	310.00	1,000.00	650.00	1,500.00
Share of Profit/(loss) in associate company,net of tax Net Profit / (Loss) after taxes and share of profit/(loss) from associate(9+10) 1,386.16 1,637.46 1,204.68 3,023.62 2,085.56 4,920.00 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,672.90 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,672.90 1,000 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,672.90 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,672.90 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,672.90 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,672.90 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,672.90 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,672.90 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,647.94 1,172.51 3,057.85 2,106.67 1,982.60 1,647.94 1,172.51 3,057.85 2,106.67 1,982.60 1,647.94 1,447.94 1,647.94 1,447.94 1,647.94 1,447.94 1,646.87 1,467.94 1,447.94 1,447.88 1,646.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466.87 1,466		(b) Current Tax relating to Earlier Period/Year	-	-	-	-	-	12.79
Net Profit / (Loss) for the Period/Year (7-8)		(c) Deferred Tax	98.20	15.56	1.27	113.76	48.65	177.89
Share of Profit/(loss) in associate company,net of tax Net Profit / (Loss) after taxes and share of profit/(loss) from associate(9+10) Other Comprehensive Income (OCI): (i) Items that will not be reclassified to profit or Loss: (iii) Income Tax effect on the above (iii) Share of other comprehensive income in Associate (iv) Share of Income Tax effect on the above in Associate (iv) Share of Income Tax effect on the above in Associate (iv) Share of Income Income/(loss), net of tax Total Comprehensive Income for the Period/Year (11+12) Earning Per Equity Share of Re.1/- each Basic / Diluted (not annualised) Paid-up equity share capital (Face Value of Re.1/- each) Reserves excluding Revaluation Reserve 10			568.20	545.56	311.27	1,113.76	698.65	1,690.68
Net Profit / (Loss) after taxes and share of profit/(loss) from associate(9+10) 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200	9	Net Profit / (Loss) for the Period/Year (7-8)	1,386.16	1,637.46	1,204.68	3,023.62	2,085.56	4,920.00
Net Profit / (Loss) after taxes and share of profit/(loss) from associate(9+10) 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200 1,409.91 1,647.94 1,172.51 3,057.85 2,106.67 4,982.60 1,200	10	Share of Profit/(loss) in associate company,net of tax	23.75	10.48	(32.17)	34.23	21.11	62.60
(iii) Income Tax effect on the above (1.51) 0.49 2.07 (1.02) 3.97 (1.77 (iiii) Share of other comprehensive income in Associate (iv) Share of Income Tax effect on the above in Associate (iv) Share of Income Tax effect on the above in Associate (0.14) (0.14) (0.35) (0.27) (0.71) (0.52 (0.			1,409.91	1,647.94		3,057.85	2,106.67	4,982.60
(iii) Share of other comprehensive income in Associate (iv) Share of Income Tax effect on the above in Associate Total Other Comprehensive Income/(loss), net of tax Total Comprehensive Income for the Period/Year (11+12) 13 Total Comprehensive Income for the Period/Year (11+12) 14 Earning Per Equity Share of Re. 1/- each Basic / Diluted (not annualised) Paid-up equity share capital (Face Value of Re. 1/- each) Reserves excluding Revaluation Reserve		(i)Items that will not be reclassified to profit or Loss:	5.99	(1.94)	(8.23)	4.05	(15.77)	7.04
(iv) Share of Income Tax effect on the above in Associate Total Other Comprehensive Income/(loss), net of tax 13 Total Comprehensive Income for the Period/Year (11+12) 14 Earning Per Equity Share of Re.1/- each Basic / Diluted (not annualised) Paid-up equity share capital (Face Value of Re.1/- each) Reserves excluding Revaluation Reserve (0.14) (0.14) (0.35) (0.27) (0.71) (0.52) 4.87 (1.06) (5.12) 3.81 (9.76) 6.74 1.67 1.95 1.39 3.61 2.49 5.89 846.52 846.52 846.52 846.52 846.52		(ii)Income Tax effect on the above	(1.51)	0.49	2.07	(1.02)	3.97	(1.77)
Total Other Comprehensive Income/(loss),net of tax 4.87 (1.06) (5.12) 3.81 (9.76) 6.74 Total Comprehensive Income for the Period/Year (11+12) 1.4 Earning Per Equity Share of Re.1/- each Basic / Diluted (not annualised) Paid-up equity share capital (Face Value of Re.1/- each) Reserves excluding Revaluation Reserve			0.53	0.52	1.39	1.05	2.75	1.99
13 Total Comprehensive Income for the Period/Year (11+12) 14 Earning Per Equity Share of Re.1/- each Basic / Diluted (not annualised) Paid-up equity share capital (Face Value of Re.1/- each) Reserves excluding Revaluation Reserve 13 Total Comprehensive Income for the Period/Year (11+12) 14 1.67 1.95 1.39 3.61 2.49 5.89 846.52 846.52 846.52 846.52 846.52 846.52								(0.52)
14 Earning Per Equity Share of Re.1/- each Basic / Diluted (not annualised) Paid-up equity share capital (Face Value of Re.1/- each) Reserves excluding Revaluation Reserve 1.67 1.95 1.39 3.61 2.49 5.89 846.52 846.52 846.52 846.52 846.52		Total Other Comprehensive Income/(loss),net of tax	4.87	(1.06)	(5.12)	3.81	(9.76)	6.74
Basic / Diluted (not annualised) Paid-up equity share capital (Face Value of Re.1/- each) Reserves excluding Revaluation Reserve 846.52 846.52 846.52 846.52	13	Total Comprehensive Income for the Period/Year (11+12)	1,414.78	1,646.87	1,167.38	3,061.66	2,096.91	4,989.34
15 Reserves excluding Revaluation Reserve	14		1.67	1.95	1.39	3.61	2.49	5.89
		Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52
	15		per(52,786.37

Consolidated Un-Audited Statement of Assets and Liabilities as at 30th September, 2024

(Rs.in Lakhs)

			(RS.In Lakns)
Sr.		As at	As at
574570.00	Particulars	30.09.2024	31.03.2024
No.		(Unaudited)	(Audited)
Α	ASSETS		(* ************************************
	Non-Current Assets		
	(a) Property, Plant and Equipment	42,380.29	42 410 00
		•	43,418.90
	(b) Capital Work-in-Progress	9,449.64	3,027.17
	(c) Right-of-use Assets	10.65 246.39	40.98
	(d) Intangible Assets		265.95
	(e) Financial Assets:		
	(i) Investments		1,093.78
	(ii) Bank Balances	296.17	268.83
	(iii) Other Financial Assets	564.90	517.05
	(f) Other Non-Current Assets	1,236.80	1,387.12
	Sub Total :Non-Current Assets		50,019.78
2	Current Assets		
	(a) Inventories	31,527.16	23,369.78
	(b) Financial Assets	0.,0270	20,000.70
	(i) Trade Receivables	21,337.88	23,623.32
	(ii) Cash and Cash Equivalents	890.06	3,603.95
		090.00	3,603.93
	(iii) Bank Balances		
	(Other than (ii) above)	16.54	16.30
	(iv) Other Financial Assets	1,182.51	327.86
	(c) Other Current Assets	3,112.85	2,275.45
	(d) Current Tax Asset (Net)	127.22	172.82
	Sub Total : Current Assets	58,194.22	53,389.48
	TOTAL ASSETS	1,13,472.82	
	EQUITY AND LIABILITIES	1,13,472.02	1,03,409.26
В			
1	Equity:	0.40 ==	242.50
	(a) Equity Share Capital	846.52	846.52
	(b) Other Equity	55,508.46	52,786.37
	Sub-Total -Shareholders' funds	56,354.98	53,632.89
	Liabilities:		
2	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	15,061.32	12,208.63
	(ii) Lease Liabilities	-	-
	(b) Provisions	123.00	116.01
	(c) Deferred Tax Liabilities (Net)	4,393.64	4,279.89
	Sub-Total -Non-Current Liabilities	19,577.96	16,604.53
3	Current Liabilities		
	(a) Financial Liabilities		
,	(i) Borrowings	13,455.69	15,809.24
	(ii) Lease Liabilities	17.31	59.18
	(ii) Trade Payables:	17.51	39.10
		60.05	05.70
	(a) Dues to Micro & Small Enterprises (b) Dues to Creditors Otherthan Micro & Small Enterprises	60.05	95.79
		21,453.11	15,036.48
	(iii) Other Financial Liabilities	1,877.33	1,585.16
	(b) Provisions	106.60	103.04
	(c) Other Current Liabilities	569.79	482.95
	Sub-Total - Current Liabilities	37,539.88	33,171.84
	TOTAL - EQUITY AND LIABILITIES	1,13,472.82	1,03,409.26
	(1)		

SMS Pharmaceuticals Limited Consolidated Unaudited Statement of Cash Flow for the Half Year Ended September 30,2024

(Rs.in Lakhs) For the Half Year For the Year ended S No **Particulars** ended 30.09.2024 31.03.2024 Α Cash Flow from Operating Activities Profit Before Tax 4,137.38 6,610.68 Adjustments for: Depreciation and Amortisation Expense 1,700.18 3,151.57 Interest Income (9.52)(16.77)Interest on lease liability 10.80 12.00 Interest on Borrowings 847.20 2,235.79 Provision for Employee Benefits 13.58 (20.33)Amortisation of Transaction Cost on Borrowings 7.34 15.55 Profit on Sale of Assets (2.25)(4.27)Loss on Sale of Assets 0.54 Unrealized Profit in Associate Company Sales 35.03 22.49 6,739.74 12,007.25 Change in Operating Assets and Liabilities (Increase)/Decrease in Trade Receivables 2,285.45 (8,784.70)(Increase)/Decrease in Inventories (8,157.38)(1,019.84)(Increase)/Decrease in Other Non Current Financial Assets (47.85)(8.55)(Increase)/Decrease in Other Non Current Asset 150.32 (826.08)(Increase)/Decrease in Other Current Financial Assets (845.44)331.15 (Increase)/Decrease in Other Current Assets (838.27)(381.61)(Increase)/Decrease in Prepaid Taxes 35.59 430.64 Increase/(Decrease) in Trade Payables 6,380.89 4,386.77 Increase/(Decrease) in Other Current Financial Liabilities 67.05 224.61 Increase/(Decrease) in Other Current Liabilities 86.84 192.83 (882.80)(5,454.78)Cash generated from Operations 5,856.94 6,552.47 (1,540.00) Income Taxes Paid (990.00)Net Cash Inflow from Operating Activities "A" 4,866.94 5,012.47 Cash flow from Investing Activities Purchase of Property, Plant and Equipment (7,117.18)(5,216.00)Sale of Property, Plant and Equipment 3.20 8.80 Investment in Deposits (0.24)(0.65)Investment in Margin Money Deposits (27.34)(15.22)Interest Received on Deposits 0.30 15.87 Net Cash Inflow (Outflow) from Investing Activities "B" (7,141.26)(5,207.20)Cash Flow from Financing Activities Proceeds from Long Term Borrowings 5,034.00 4,508.63 Repayment of Long Term Borrowings (2,267.35)(3,776.36)Net Proceeds from Short Term Borrowings (2,278.55)2,020.71 Interest paid on Borrowings (874.05)(2,175.16)Repayment of Lease Liability (52.67)(103.74)Proceeds from Share Warrants(Net of issue expenses) (0.97)2,847.78 Dividend Paid to company's shareholders (253.96)Net Cash Inflow (Outflow) from Financing Activities "C" (439.59)3,067.90 Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C) (2,713.89)2,873.17 Cash and Cash Equivalents at the beginning of the Financial Year 3,603.95 730.78 armace Cash and Cash Equivalents at end of the Year 890.06 3,603.95

Hyderabad

Notes:

- The above Consolidated un-audited financial results for the quarter ended September 30, 2024 have been reviewed by the Audit Committee on November 07, 2024 and approved by the Board of Directors at their meeting held on November 08, 2024. The statutory auditors of the Company have carried out a limited review on consolidated financial results for the quarter ended September 30, 2024 and expressed an unmodified conclusion thereon.
- These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- VKT Pharma Private Limited is considered as an Associate Company for the consolidation in which the company holds 34.83% as on September 30, 2024 in their equity. Accordingly the results include appropriate share of the results of the said Associate. The Company has another Joint Venture "Chemo SMS Enterprises SL" in which there were no financial operations during the reporting period.
- 4 Consolidated Financial Statements have been prepared by applying Accounting Standard "Ind AS 28 "Investments in Associates and Joint Ventures" as applicable under the Companies Act, 2013 and applicable rules there under.
- 3 The Group is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- As approved by the Members of the company at the 36th Annual General Meeting held on September 30,2024, the company has disbursed on October 04, 2024 a dividend of Re.0.40 per equity share of Re.1/- each for the year ended March 31, 2024, aggregating to Rs.308.36 lakhs (Including an amount of Rs 30.25 lakhs towards Tax Deducted at Source).

5 Figures for the previous period have been reclassified/ regrouped wherever necessary to confirm to current period's classification.

For SMS Pharmaceuticals Limited

Ramesh Babu Potluri
Chairman and Managing Director

DIN: 00166381

Place: Hyderabad

Date: 08 November, 2024